Applied Health Economics and Health Policy

Papers
(The TQCC of Applied Health Economics and Health Policy is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Cost-Effectiveness of Perinatal Depression Screening: A Scoping Review226
Partnerships in Public Health Economics: Reflective Lessons from UK Obesity Research113
Therapy, Pills and Unmet Needs for Financial Reasons: Socioeconomic Inequalities and Inequities in Access to Mental Health Care in Spain 2014–202055
Cost-Effectiveness and Value of Information Analyses of Caplacizumab for the Treatment of Thrombotic Thrombocytopenic Purpura in Brazil43
Improving Consumer Engagement in Health Technology Assessment and Decision Making: Lessons from ‘Values in Science’39
Which Factors are Holding up the Integration of the Environmental Impact of Health Technologies in Health Technology Assessment? Insights from a Multi-Stakeholder Interview Study38
Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China36
Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach30
The Cost Effectiveness of Treatment Strategies for Depression in Ethiopia: A Multiple Cohort Markov Model Analysis30
Cost-Effectiveness of a Universal School-Based Mental Health Prevention Program: An Economic Modeling Study in a Limited Income Context28
Assessing the Direct Impact of Death on Discrete Choice Experiment Utilities28
Selection and Prioritization of Medical Devices for HTA Evaluation: A Systematic Review of Existing Approaches26
Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework26
Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines24
A Guideline-Implementation Intervention to Improve the Management of Low Back Pain in Primary Care: A Difference-in-Difference-in-Differences Analysis23
Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand22
The Economics of Antibiotic Resistance: A Systematic Review and Meta-analysis Based on Global Research20
Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom18
Economic Evaluation Evidence for Resource-Allocation Decision Making: Bridging the Gap for Local Decision Makers Using English Case Studies18
Psychometric Evaluation of the PedsQL GCS and CHU9D in Australian Children and Adolescents with Common Chronic Health Conditions18
Local Level Economic Evaluation: What is it? What is its Value? Is it Sustainable?17
Politicised Changes to the NICE Threshold Risk Making Cost-Effectiveness Analysis Performative, Not Informative17
Acknowledgement to Reviewers16
A Cost–Utility Analysis of Surgical Site Infection Prevention: Broadening the Scope15
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?15
Correction to: Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis15
Financing Comprehensive Immunization Services in Lao PDR: A Fiscal Space Analysis From a Public Policy Perspective15
How is Value Defined in Molecular Testing in Cancer? A Scoping Review15
The Economic Cost of Rising Non-communicable Diseases in India: A Systematic Literature Review of Methods and Estimates15
A Systematic Review of the World’s Largest Government Sponsored Health Insurance Scheme for 500 Million Beneficiaries in India: Pradhan Mantri Jan Arogya Yojana15
The Price of Speed: Estimating the Impact of List Prices on Time to Availability of New Medicines in 18 European Countries14
Correction: Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?14
Estimating the Health Effects of Expansions in Health Expenditure in Indonesia: A Dynamic Panel Data Approach14
Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients14
Economic Evaluation of Bruton’s Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa13
Contextual Factors that Influence Antibiotic Prescribing: A Discrete Choice Experiment of GP Registrars13
Valuation of Costs in Health Economics During Financial and Economic Crises: A Case Study from Lebanon13
Quality-Adjusted Life Expectancy and Cost-Effectiveness Thresholds in Three High-Income Regions in Asia12
How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts12
Social Costs of Smoking in the Czech Republic12
Development of a Health Technology Assessment Quality Appraisal Checklist (HTA-QAC) for India12
Young People’s Preferences for Web-Based Mental Health Interventions for Managing Anxiety and Depression: A Discrete Choice Experiment11
Guiding Health Resource Allocation: Using Population Net Health Benefit to Align Disease Burden with Cost Effectiveness for Informed Decision Making11
Correction to: Different Frameworks, Similar Results? Head-to-Head Comparison of the Generic Preference-Based Health-Outcome Measures CS-Base and EQ-5D-5L11
A Systematic Review of Cost-Effectiveness Analyses of Colorectal Cancer Screening in Europe: Have Studies Included Optimal Screening Intensities?11
Cost-Effectiveness of Anti-retroviral Adherence Interventions for People Living with HIV: A Systematic Review of Decision Analytical Models11
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes11
Measures of Performance and Clinical Superiority Thresholds for ‘Test-and-treat’ Predictive Biomarkers11
Projected Impact on Labour Productivity Costs of Cancer-Related Premature Mortality in Europe 2018–204011
Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study11
Societal Preferences for Assessment Pathways of Rare Disease Drugs: A Discrete Choice Experiment11
Collaborating for Affordable Patient Access to Medicines: Review of the First Decade of the Beneluxa Initiative in Pharmaceutical Policy10
Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges10
Sedaconda ACD-S for Sedation with Volatile Anaesthetics in Intensive Care: A NICE Medical Technologies Guidance10
Machine Learning-Assisted Health Economics and Policy Reviews: A Comparative Assessment10
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older10
Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study10
Measurement of Catastrophic Health Expenditure in India: A Systematic Review and Meta-Analysis10
Trump’s Drug Pricing Order and the Domestic Economic Trade-Off10
Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective10
Analysing the Efficiency of Health Systems: A Systematic Review of the Literature10
A Head-On Comparison of EQ-VT- and Crosswalk-Based EQ-5D-5L Value Sets9
The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework9
Mechanisms Considering Public Investment in Pricing and Reimbursement Decisions of Medicines and Other Health Technologies: A Scoping Review9
Discrete Event Simulation in R using the ‘Simmer’ Package for Health Economic Modelling: A Tutorial and Illustration in Colon Cancer9
The Health Economics of Genomic Technologies: A Growing Evidence Base on Value9
A Systematic Review of Economic Evaluations on Interventions Targeting Insomnia or Hypersomnia8
Ensuring Epidemiological Consistency in Risk-Stratified Cancer Screening Models: A Novel Approach Based on Flemish Breast Cancer Screening8
The Limitations and Potentials of Evaluating Economic Aspects of Community-Based Health Promotion: A Critical Review7
Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework7
Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold7
Headroom Analysis for Early Economic Evaluation: A Systematic Review7
EQ-5D-5L Population Norms for Italy7
Costs and Budget Impact of a Health System Strengthening Intervention for Hypertension and Cardiovascular Disease Care in Ghana7
Exploring Consumer Preferences for Cannabis Vaping Products to Support Public Health Policy: A Discrete Choice Experiment7
The Price of National Pharmaceutical Pricing in the EU: A Proposal for “Common Procurement”7
A Systematic Review of Health Economic Evaluations and Budget Impact Analyses to Inform Healthcare Decision-Making in Central America7
Estimated Carbon Savings from Changing Surgical Trends in Primary Elective Total Hip Arthroplasty in England: A Retrospective Observational Study7
Integrating Equity in Topic Selection for Orphan Medicinal Products: Policy Implications for Health Technology Assessment in Rare Diseases7
Health Reform in Aotearoa New Zealand: Insights on Health Equity Challenges One Year On6
Model-Based Economic Evaluations of Interventions for Dementia: An Updated Systematic Review and Quality Assessment6
Discrete Choice Experiments in Health State Valuation: A Systematic Review of Progress and New Trends6
Structured Expert Elicitation to Inform Long-Term Survival Extrapolations in Advanced Renal Cell Carcinoma6
Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment6
Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe6
The Impact of Value-Based Payment Models for Networks of Care and Transmural Care: A Systematic Literature Review6
Preferences for Digital Mental Health Services in Urban China: A Discrete Choice Experiment6
New Horizons? Assessing General Public Preferences for a Wellbeing Economy in the Post-COVID-19 World6
Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland6
Productivity Losses due to Health Problems Arising from COVID-19 Pandemic: A Systematic Review of Population-Level Studies Worldwide6
A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany6
Use of Decision-Analytic Modelling to Assess the Cost-Effectiveness of Diagnostic Imaging of the Spine, Shoulder, and Knee: A Scoping Review6
Modelled Distributional Cost-Effectiveness Analysis of Childhood Obesity Interventions: A Demonstration6
Cost-Effectiveness and Value of Information Analysis of an Ambient Intelligent Geriatric Management (AmbIGeM) System Compared to Usual Care to Prevent Falls in Older People in Hospitals6
The Impact of Alteplase Coverage on Health Equity for the Treatment of Ischemic Stroke in the USA: A Distributional Cost-Effectiveness Analysis6
Correction: Economic Evaluations of Robotic-Assisted Surgery: Methods, Challenges and Opportunities6
The Role of Price Variation in Economic Analyses for Cancer Screenings: A Rapid Review6
Genetic Test Utilization and Cost among Families of Children Evaluated for Genetic Conditions: An Analysis of USA Commercial Claims Data6
0.55065488815308